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Clinicopathologic features and epidermal growth factor receptor 
mutations associated with epithelial-mesenchymal transition in 
non-small cell lung cancer
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Small molecule inhibitors of epidermal growth factor receptor (EGFR), 
geﬁtinib and erlotinib, have been extensively studied in Non-small cell 
lung cancer (NSCLC) patients. The discovery of molecular biomark-
ers that identify the subgroups of NSCLC patients beneﬁting from 
EGFR tyrosine kinase inhibitor (TKI) has become an important area of 
investigation. Recently studies, which suggested that epithelial-mes-
enchymal transition (EMT) in tumors decreases cellular requirements 
for EGFR signaling pathway, provided a molecular signature (e.g. 
E-cadherin-positive) to deﬁne NSCLC patients most likely to respond 
to treatment targeted EGFR TKI. We performed immunohistochemi-
cal analyses of epithelial or mesenchymal phenotypic characteristics 
of unselected tumor specimens and compared EMT phenotypes with 
clinicopathologic features and EGFR genotypes. We observed 22 speci-
mens with E-cadherin-positive and 42 with vimentin-positive among 62 
NSCLC tumors. Kappa coefﬁcient analysis showed agreement with the 
EMT status of tumor specimens determined by E-cadherin staining and 
vimentin staining. Among NSCLC patients, E-cadherin-positive was 
statistically signiﬁcantly more frequent in EGFR mutants versus wild-
types (77.78% versus 18.18%; P<0.0001), and in females versus males 
(54.55% versus 25%; P=0.02). Logistic regression analysis conﬁrmed 
the correlation of EMT status with EGFR genotype (Odds ratio, 0.077; 
95% conﬁdence interval, 0.019 to 0.306; P=0.0003).It is concluded that 
EMT is associated with EGFR mutations in NSCLC and may account 
for primary resistance of NSCLC to EGFR TKI. 
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Estrogen and progesterone receptors in women with non-small-cell 
lung cancer: a potential therapeutic target?
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Background: A role of estrogens in the lung cancer development is 
suggested by gender-related differences in incidence and prognosis. 
Women affected by NSCLC show higher levels of sexual hormones than 
healthy females (Stabile LP et al, 2004). Also, the premenopausal status 
is associated with advanced stage, unfavourable histology and poorly 
differentiated tumors. The expression of estrogen receptor (ER) and pro-
gesterone receptor (PgR) could be involved in lung tumor progression 
and conﬂicting data emerged about the different expression of these re-
ceptors in the two genders. ERa is more likely to be expressed in women 
than men (Patel JD et al, 2005) and its overexpression is correlated 
with a poor outcome and with a smoking history (Kawai H et al, 2005). 
Preclinical studies reported an antiproliferative effect of antiestrogens 
in NSCLC cell lines and in vivo tumor xenografts but the potential for 
using ER inhibitors to treat NSCLC remains to be determined. Our goal 
was to assess ER and PgR expression in NSCLC females and to analyze 
their correlation with the clinical and pathological features in order to 
identify useful information for a therapeutic selection.
Methods: ERα and PgR expression was assessed by standard immu-
noistochemical methods using archival formalin-ﬁxed, parafﬁn-embed-
ded specimens. Univariated analysis of correlation between hormonal 
receptors and history of smoking, stage of disease and histology was 
performed with χ2 test. Kaplan-Meier survival curves were utilized to 
verify the potential impact of their expression on the clinical outcome.
Results: A total of 44 Italian women with a median age of 66 years 
(range 27-83) were evaluated. Their clinical-pathological features 
were: pre-menopausal/post-menopausal status 9/35, smokers/non 
smokers 18/26, adenocarcinoma/squamouscarcinoma/other histology 
34/2/8, stage I/II/III/IV 9/2/20/13, epidermal growth factor receptor 
(EGFR)+/EGFR- 31/13. 35 (80%) women received one or more lines 
of chemotherapy. PgR was expressed in 5 (11%) patients (pts) while no 
expression of ERα was found. No statistically signiﬁcant relationship 
emerged among PgR and ER expression and history of smoking, stage 
of disease and histology. No statistically signiﬁcant correlation was 
found between ER and PgR expression and survival.
Conclusions: Our results show an absent ERα expression and a low 
PgR expression in Western women affected by NSCLC. This suggests 
the need to better understand the biological pattern of NSCLC females, 
in order to potentially identify subsets of pts who could beneﬁt of an 
antiestrogen. This is particularly relevant considering the new data 
(Traynor AM et al, 2005) about the potential efﬁcacy of a combined 
treatment including both ER and EGFR inhibitors, based on their 
known cross-talking.
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VEGFR1-2, C-Kit, HER2 and CD20 immunostaining in thymic 
epithelial tumors staged according to the WHO.
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Background: Thymic epithelial tumors (TET) have shown modest 
responses to standard chemotherapy. The aim of this study was to iden-
tify biological markers with potential predictive value. Five markers 
(CD20, HER2, c-kit and VEGFR1-2) were selected for evaluation in 
patients with advanced TET. 
Methods: 93 TET (WHO classiﬁed as 4 A, 25 AB, 9 B1, 26 B2, 11 
B3, 10C, 5 micronodular TET, 1 metaplasic thymoma and 2 carcinoids 
TET) including 3 paired primary/secondary tumor (B2/B3/C) were 
centrally reviewed. Each tumor was assessed by immunohistochemistry 
with a score from 0 to 3+.
Results: CD20 staining was positive (i.e. more than 10% positive cells) 
in 11 TET WHO AB (45%), while none of the others TET (WHO A, 
B1-3, C) were positive. C-kit was strongly expressed (3+, 100% of the 
